The Prevalence of HIV Drug Resistance among Treatment-failure Individuals and Treatment-naïve Individuals in China: A Meta-analysis.

Jing WU; Jessie Norris; Hui Xin Liu; Zheng LI; Ying Ying SU; Lin Zhu; Ning Wang

Return

The Prevalence of HIV Drug Resistance among Treatment-failure Individuals and Treatment-naïve Individuals in China: A Meta-analysis.

Author: Jing WU ^{1
,

2} ; Jessie NORRIS ³ ; Hui Xin LIU ³ ; Zheng LI ³ ; Ying Ying SU ³ ; Lin ZHU ³ ; Ning WANG ³
Author Information

1. National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China
2. School of Agroforestry & Medicine, the Open University of China, Beijing 100039, China.
3. National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China.
Publication Type:Journal Article
Keywords: China; Drug resistance; HIV; Meta-analysis
MeSH: Anti-HIV Agents; administration & dosage; therapeutic use; China; Drug Resistance, Viral; genetics; HIV Infections; drug therapy; epidemiology; Humans; Prevalence; Randomized Controlled Trials as Topic; Time Factors; Treatment Failure
From: Biomedical and Environmental Sciences 2014;27(11):858-871
CountryChina
Language:English
Abstract:
OBJECTIVETo understand drug resistance prevalence among treatment-failure and treatment-naïve HIV-positive individuals in China.
METHODSWe searched five electronic databases (Wanfang, CNKI, CQVIP, SinoMed, and Pubmed) for studies of HIV drug resistance. Random-effects models were carried out to estimate the prevalence of drug resistance among treatment-failure and treatment-naïve individuals, respectively.
RESULTSThe estimated nationwide rates of HIV drug resistance to any-class drugs among treatment-failure and treatment-naïve individuals were 57% (95% CI: 49%-65%) and 3.23% (95% CI: 2.47%-4.07%), respectively. Among the drug classes, the prevalence of resistance to PIs was low (1.45%; 95% CI: 0.73%-2.33%) in treatment-failure individuals, although high rates of resistance to NNRTIs (54%; 95% CI: 45%-63%) and NRTIs (40%; 95% CI: 32%-49%) were found. Resistance to any-class drugs, NNRTIs and NRTIs manifested regional differences, but resistance to PIs did not. Positive correlations were observed between resistance to NNRTIs and NRTIs among treatment-failure and treatment-naïve individuals, respectively.
CONCLUSIONThe prevalence of HIV drug resistance to NNRTIs and NRTIs among treatment-failure individuals was high. In contrast, the prevalence of drug resistance among treatment-naïve individuals was low. The epidemics of drug resistance matched current treatment strategies and interventions in China. Surveillance for HIV drug resistance is necessary to assess the sustainability and durability of current treatment regimens.